TB Research

Safety and treatment completion of latent tuberculosis infection treatment in the elderly population—A prospective observational study in Taiwan

Jia-Yih Feng, Wei-Chang Huang, Shu‐Min Lin, Tsai-Yu Wang, Susan Shin‐Jung Lee, Chin‐Chung Shu, Sheng‐Wei Pan, Chung‐Yu Chen, et al. (13 authors)

International Journal of Infectious Diseases · 2020-05

Abstract

BackgroundThe detection and treatment of latent tuberculosis infection (LTBI) is a key step in eliminating tuberculosis (TB), but information on safety and on treatment interruption in elderly LTBI patients remains limited.MethodsThis multicenter prospective observational study included individuals with LTBI who underwent preventive therapy. Incidents of systemic adverse reactions (SARs) and treatment interruption rates in an elderly group (≥60 years old) and a young group (<60 years old) were analyzed.ResultsA total of 406 LTBI patients, comprising 167 elderly and 239 young patients, were included in the analyses. The incidence of SARs was similar in the elderly group (18%) and the young group (15.1%). Being middle-aged (35–59 years), body mass index <23 kg/m2, a regimen of 3 months of once-weekly rifapentine plus isoniazid, and end-stage renal disease were independent factors associated with SARs. The treatment interruption rate was similar between the elderly group (21.6%) and the young group (15.9%). LTBI patients aged ≥80 years with SARs had the highest risk of treatment interruption.ConclusionsThe occurrence of SARs was similar in the elderly (≥60 years old) and young (<60 years old) LTBI patients receiving preventive therapy. Extremely old (≥80 years old) LTBI patients had a higher treatment interruption rate, especially when they had SARs.

MeSH terms

  • Medicine
  • Rifapentine
  • Observational study
  • Tuberculosis
  • Latent tuberculosis
  • Regimen
  • Incidence (geometry)
  • Population
  • Adverse effect
  • Pediatrics
  • Prospective cohort study
  • Young adult
  • Internal medicine
  • Surgery